Free Trial
NASDAQ:LUCD

Lucid Diagnostics (LUCD) Stock Price, News & Analysis

Lucid Diagnostics logo
$1.22 -0.05 (-3.57%)
As of 10:05 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Lucid Diagnostics Stock (NASDAQ:LUCD)

Key Stats

Today's Range
$1.20
$1.27
50-Day Range
$0.98
$1.26
52-Week Range
$0.73
$1.80
Volume
161,424 shs
Average Volume
982,176 shs
Market Capitalization
$131.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.55
Consensus Rating
Buy

Company Overview

Lucid Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

LUCD MarketRank™: 

Lucid Diagnostics scored higher than 58% of companies evaluated by MarketBeat, and ranked 455th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lucid Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lucid Diagnostics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Lucid Diagnostics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.84) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lucid Diagnostics is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lucid Diagnostics is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Lucid Diagnostics' valuation and earnings.
  • Percentage of Shares Shorted

    13.09% of the float of Lucid Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lucid Diagnostics has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Lucid Diagnostics has recently increased by 10.23%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lucid Diagnostics does not currently pay a dividend.

  • Dividend Growth

    Lucid Diagnostics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.09% of the float of Lucid Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lucid Diagnostics has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Lucid Diagnostics has recently increased by 10.23%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Lucid Diagnostics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Lucid Diagnostics this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for LUCD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lucid Diagnostics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $102,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 6.80% of the stock of Lucid Diagnostics is held by insiders.

  • Percentage Held by Institutions

    74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lucid Diagnostics' insider trading history.
Receive LUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LUCD Stock News Headlines

INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
Lucid Diagnostics (LUCD) Gets a Buy from BTIG
Wall Street Zen Upgrades Lucid Diagnostics (NASDAQ:LUCD) to Hold
See More Headlines

LUCD Stock Analysis - Frequently Asked Questions

Lucid Diagnostics' stock was trading at $0.8187 at the beginning of the year. Since then, LUCD shares have increased by 53.9% and is now trading at $1.26.

Lucid Diagnostics Inc. (NASDAQ:LUCD) issued its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.26) earnings per share for the quarter. The company earned $1.04 million during the quarter.
Read the conference call transcript
.

Lucid Diagnostics (LUCD) raised $75 million in an initial public offering on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.

Top institutional investors of Lucid Diagnostics include Geode Capital Management LLC (1.46%), New York State Common Retirement Fund (0.08%), Parallel Advisors LLC (0.04%) and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. (0.03%). Insiders that own company stock include Dennis Matheis and Stanley Lapidus.
View institutional ownership trends
.

Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lucid Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Netflix (NFLX), Clean Energy Fuels (CLNE) and Baidu (BIDU).

Company Calendar

Last Earnings
3/26/2024
Today
8/28/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:LUCD
CIK
1799011
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

High Price Target
$7.75
Low Price Target
$2.00
Potential Upside/Downside
+181.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.53 million
Net Margins
-1,476.35%
Pretax Margin
-1,267.41%
Return on Equity
N/A
Return on Assets
-120.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.15
Quick Ratio
1.13

Sales & Book Value

Annual Sales
$4.35 million
Price / Sales
31.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.43) per share
Price / Book
-2.93

Miscellaneous

Outstanding Shares
108,480,000
Free Float
101,101,000
Market Cap
$136.68 million
Optionable
No Data
Beta
1.21

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:LUCD) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners